Business context and reporting period
Filing identity differs from the request metadata: the supplied 10-K is for BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), not ANI Pharmaceuticals, Inc. It covers the fiscal year ended December 31, 2011, rather than a standalone 2011 fourth quarter. The filing reports unaudited fourth-quarter figures separately.
BioSante was a development-stage specialty pharmaceutical company focused on female sexual health and oncology. Its portfolio included LibiGel, GVAX cancer vaccines and The Pill-Plus in development, plus licensed products Elestrin and a male testosterone gel.
Financial results and liquidity
| Metric | FY 2011 | FY 2010 |
|---|---|---|
| Revenue | $0.44 million | $2.47 million |
| Research and development expense | $44.18 million | $39.71 million |
| General and administrative expense | $6.98 million | $5.94 million |
| Net loss | $51.61 million | $46.20 million |
| Basic and diluted loss per share | $0.52 | $0.70 |
| Net cash used in operating activities | $47.87 million | $40.10 million |
| Cash and cash equivalents at year-end | $57.23 million | $38.16 million |
- FY 2011 revenue fell 82.4%, mainly because 2010 included a non-refundable payment associated with the Elestrin license amendment. Most 2011 revenue was royalty revenue, substantially offset by royalties payable to Antares.
- R&D expense rose 11.3%, primarily due to LibiGel’s three Phase III studies. Net loss increased about $5.4 million, while loss per share decreased because the weighted-average share count increased substantially.
- Cash from financing was $67.66 million, principally from 2011 equity offerings; investing activities used $0.72 million. Year-end total assets were $62.38 million, total liabilities $24.56 million, and stockholders’ equity $37.82 million. No meaningful operating margin is presented; revenue was small relative to development costs.
- At December 31, 2011, the balance sheet carried $17.34 million of convertible notes at fair value; their stated principal was $20.78 million. In February 2012, BioSante issued about 11.2 million shares to cancel $9.0 million of notes, leaving $11.8 million principal outstanding as of March 12, 2012. The remaining notes mature May 1, 2013.
- Management estimated year-end cash would fund operations through mid-2013 if the LibiGel safety study continued, or through late 2014 if it ended in Q2 2012 and no other product-development activities occurred. These are management estimates, not assurances; the company had no credit facility and warned it might need further financing or strategic alternatives.
Fourth quarter: revenue was $114,373 and net loss was $6.65 million, versus revenue of $143,032 and net loss of $13.27 million in fourth-quarter 2010. Fourth-quarter 2011 R&D expense was $6.70 million. The filing does not provide a clear standalone fourth-quarter cash-flow figure.
Material changes and significant developments
- Two pivotal Phase III LibiGel efficacy trials, reported in December 2011, failed to meet their co-primary and secondary endpoints; results were not statistically different from placebo. This reversed the prior development plan, which had targeted an NDA submission in 2012.
- R&D spending continued to concentrate on LibiGel. The company said 2012 spending would depend on whether it continued the safety study: approximately $1.8 million per month if continued, versus minimal R&D thereafter if discontinued, assuming no new development programs.
- In February 2012, the FDA approved Teva’s male testosterone gel NDA. Commercial launch timing and BioSante’s royalty receipts remained uncertain because Teva had settled patent litigation with an Abbott subsidiary on confidential terms.
- BioSante raised approximately $68.9 million net through equity offerings in 2011. Common shares outstanding rose from 81.4 million at year-end 2010 to 109.6 million at year-end 2011; the February 2012 note exchange caused further dilution.
Outlook, risks, contingencies and unusual items
- Management was reassessing LibiGel’s future, intended to consult the FDA and expected to decide in Q2 2012 whether to continue the Phase III safety study. The independent data monitoring committee recommended continuing the study unchanged after its eighth review; the company remained blinded to treatment assignments.
- At the latest review disclosed, the safety study included 3,656 subjects and more than 5,800 subject-years of exposure, with 31 adjudicated cardiovascular events and 19 breast cancer diagnoses. The filing did not disclose treatment-arm attribution.
- The company was reviewing its GVAX portfolio and exploring in-licensing, acquisitions, partnerships and other strategic transactions. Seventeen Phase I and II GVAX studies were ongoing, primarily at Johns Hopkins and funded by outside sources, foundations or licensees.
- NASDAQ had notified BioSante that its bid price had been below $1.00 for 30 consecutive business days. It had until July 30, 2012 to regain compliance; the March 12, 2012 closing bid was $0.74. Delisting or a move to the NASDAQ Capital Market could impair liquidity and financing access.
- Two purported securities class actions filed in February 2012 alleged misleading disclosures about LibiGel. BioSante said it would defend the cases; their outcome and any potential loss were not estimable from the filing.
- Other key risks include continued losses, dependence on financing and licensees, potential inability to repay remaining notes at maturity, clinical and regulatory uncertainty, third-party manufacturing dependence, competitive pressures, potential dilution, and possible further workforce reductions. BioSante reported effective internal control over financial reporting and received unqualified audit opinions on its financial statements and internal controls.
Important facts for investors to verify
- Confirm the issuer and security: this filing is BioSante Pharmaceuticals (BPAX), not ANI Pharmaceuticals.
- Check subsequent disclosures on the LibiGel safety-study decision, FDA discussions, and any revised cash runway or spending plans.
- Verify the remaining convertible-note principal, maturity obligations and any further exchanges or financing after March 12, 2012.
- Track Teva’s launch timing and the resulting royalty economics, along with any developments in the confidential patent settlement.
- Review NASDAQ listing compliance and the status, potential costs and resolution of the securities litigation.
- Assess whether GVAX licensing, funding, clinical progress or strategic transactions produce material cash proceeds or change BioSante’s operating plans.